A preliminary nomogram model for predicting relapse of patients with primary membranous nephropathy

References

• Yokoyama H, Yamamoto R, Imai E, et al. Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: the Japan nephrotic syndrome cohort study (JNSCS). Clin Exp Nephrol. 2020;24(10):1–10.
   Web of Science ®Google Scholar
• Hu R, Quan S, Wang Y, et al. Spectrum of biopsy proven renal diseases in Central China: a 10-year retrospective study based on 34,630 cases. Sci Rep. 2020;10(1):10994.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Ando M, Katsuno T, et al. Urinary protein and renal prognosis in idiopathic membranous nephropathy: a multicenter retrospective cohort study in Japan. Ren Fail. 2018;40(1):435–441.
   PubMed Web of Science ®Google Scholar
• Huh H, Lee H, Lee JP, et al. Factors affecting the long-term outcomes of idiopathic membranous nephropathy. BMC Nephrol. 2017;18(1):104.
   PubMedGoogle Scholar
• KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–S276.
   PubMed Web of Science ®Google Scholar
• De Vriese AS, Glassock RJ, Nath KA, et al. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28(2):421–430.
   PubMed Web of Science ®Google Scholar
• Tesar V, Hruskova Z. Autoantibodies in the diagnosis, monitoring, and treatment of membranous nephropathy. Front Immunol. 2021;12:593288.
   PubMed Web of Science ®Google Scholar
• Stefan G, Stancu S, Zugravu A, et al. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy. Ren Fail. 2022;44(1):258–268.
   PubMed Web of Science ®Google Scholar
• Ji L, Gao D, Hao Y, et al. Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal. Rheumatology. 2022;62(1):181–189.
   PubMed Web of Science ®Google Scholar
• Chen T, Zhou Y, Zhu J, et al. Prediction model of renal function recovery for primary membranous nephropathy with acute kidney injury. BMC Nephrol. 2022;23(1):247.
   PubMed Web of Science ®Google Scholar
• Chapter 7: idiopathic membranous nephropathy. Kidney Int Supp. 2012;2(2):186–197.
   Google Scholar
• Yamamoto R, Imai E, Maruyama S, et al. Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan nephrotic syndrome cohort study (JNSCS). Clin Exp Nephrol. 2020;24(6):526–540.
   PubMed Web of Science ®Google Scholar
• Oh J, Won HY, Kang SM. Uric acid and cardiovascular risk. N Engl J Med. 2009;360(5):539.
   PubMedGoogle Scholar
• Liu B, Zhao L, Yang Q, et al. Hyperuricemia and hypertriglyceridemia indicate tubular atrophy/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy. Int Urol Nephrol. 2021;53(11):2321–2332.
   PubMed Web of Science ®Google Scholar
• Zhang J, Pan M, Zhang J, et al. Serum uric acid is an independent predictor of renal outcomes in patients with idiopathic membranous nephropathy. Int Urol Nephrol. 2019;51(10):1797–1804.
   PubMed Web of Science ®Google Scholar
• Wasilewska A, Zoch-Zwierz W, Tobolczyk J, et al. High-sensitivity C-reactive protein (hs-CRP) level in children with nephrotic syndrome. Pediatr Nephrol. 2007;22(3):403–408.
   PubMed Web of Science ®Google Scholar
• Festa A, D’Agostino R, Howard G, et al. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the insulin resistance atherosclerosis study. Kidney Int. 2000;58(4):1703–1710.
   PubMed Web of Science ®Google Scholar
• Lee T, Chung Y, Poulton CJ, et al. Serum albumin at partial remission predicts outcomes in membranous nephropathy. Kidney Int Rep. 2020;5(5):706–717.
   PubMed Web of Science ®Google Scholar
• Thompson A, Cattran DC, Blank M, et al. Complete and partial remission as surrogate end points in membranous nephropathy. J Am Soc Nephrol. 2015;26(12):2930–2937.
   PubMed Web of Science ®Google Scholar
• Qiu TT, Zhang C, Zhao HW, et al. Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: a systematic review and meta-analysis of 21 clinical trials. Autoimmun Rev. 2017;16(2):136–145.
   PubMed Web of Science ®Google Scholar
• Ramachandran R, Yadav AK, Kumar V, et al. Two-Year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide. Kidney Int Rep. 2017;2(4):610–616.
   PubMed Web of Science ®Google Scholar
• van de Logt AE, Dahan K, Rousseau A, et al. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. Kidney Int. 2018;93(4):1016–1017.
   PubMed Web of Science ®Google Scholar
• van den Brand JA, van Dijk PR, Hofstra JM, et al. Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol. 2014;25(1):150–158.
   PubMed Web of Science ®Google Scholar
• Ramachandran R, Hn HK, Kumar V, et al. Tacrolimus combined with corticosteroids versus modified ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial. Nephrology (Carlton). 2016;21(2):139–146.
   PubMed Web of Science ®Google Scholar
• Khan S, Bolton WK. Balancing cancer risk and efficacy of using cyclophosphamide to treat idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(6):1001–1004.
   PubMed Web of Science ®Google Scholar
• Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931–938.
   PubMed Web of Science ®Google Scholar
• Cattran DC, Brenchley PE. Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int. 2017;91(3):566–574.
   PubMed Web of Science ®Google Scholar
• Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381(1):36–46.
   PubMed Web of Science ®Google Scholar
• He P, Yu X, Zha Y, et al. Microhematuria enhances the risks of relapse and renal progression in primary membranous nephropathy. Front Med (Lausanne). 2021;8:704830.
   PubMed Web of Science ®Google Scholar
• Moreno JA, Sevillano A, Gutierrez E, et al. Glomerular hematuria: cause or consequence of renal inflammation?. Int J Mol Sci. 2019;20(9):2205.
   Web of Science ®Google Scholar
• Beck LJ, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Fervenza FC, Remuzzi G. Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol. 2017;13(9):563–579.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol. 2015;26(10):2545–2558.
   PubMed Web of Science ®Google Scholar
• Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended Follow-Up. J Am Soc Nephrol. 2017;28(1):348–358.
   PubMed Web of Science ®Google Scholar
• Rao SJ, Shen Q, Wang HM, et al. The association of anti-PLA2R with clinical manifestations and outcomes in idiopathic membranous nephropathy: a meta-analysis. Int Urol Nephrol. 2020;52(11):2123–2133.
   PubMed Web of Science ®Google Scholar
• Ruan ZB, Liang HX, Wang F, et al. Influencing factors of recurrence of nonvalvular atrial fibrillation after radiofrequency catheter ablation and construction of clinical nomogram prediction model. Int J Clin Pract. 2022;2022:8521735.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Che X, Ni Z, et al. Association of relapse with renal outcomes under the current therapy regimen for IgA nephropathy: a Multi-Center study. PLoS One. 2015;10(9):e137870.
   Web of Science ®Google Scholar